Clinical trials: Healthy Blood Donors
Blood Stem Cell Harvest Failure
Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers
With a standard mobilization regimen using G-CSF, approximately 5% of allogeneic donors does not mobilize enough CD34+ cells to reach an optimal dose for transplantation and are therefore called "poor mobilizers".
- Trial name
- MOBIL1 (NCT01954914)
- Testing
- Plerixafor
- Where
- 3 sites in Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Malignant Lymphoma, Stem Cell Type
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Stem cells can be transplanted from a healthy donor to a patient to combat blood cancers and other disorders. This process is called stem cell transplantation. Stem cells normally live in the bone marrow.
- Trial name
- NCT01403896
- Testing
- Plerixafor (Mozobil), Plerixafor + G-CSF
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stephen Couban
Healthy Volunteers
Trima Accel® System Post Count Algorithm Study
The purpose of this study is to optimize collected platelet yields in single and double platelet collections, while maintaining donor postplatelet count of >100,000/µL.
- Trial name
- NCT02684630
- Testing
- Trima Accel System
- Where
- 2 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Terumo BCT
Allogeneic Granulocyte Donation
Improving White Blood Cell Collection From Healthy Donors
Background: White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells.
- Trial name
- NCT01553214
- Testing
- Filgrastim, Dexamethasone
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumors
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Background \& Rationale: About 75% of US population living today will not die of cancer. There has been a recent report of a colony of cancer-resistant mice developed from a single male mouse that unexpectedly survived challenges…
- Trial name
- NCT00900497
- Testing
- White Blood Cells/Granulocytes
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dipnarine Maharaj
Aortic Aneurysm
Reference Values of Circulating Endothelial Progenitor Cells
Circulating endothelial progenitor cells CD34+144+CD14- et CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. However reference values have not yet been determined.
- Trial name
- ANOPEC2 (NCT01918969)
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hopital Jean Minjoz
Healthy
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
The purpose of the study is to: Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors Assess the safety among NMDP donors of…
- Trial name
- NCT00785525
- Testing
- Filgrastim
- Where
- 4 sites in United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Center for International Blood and Marrow Transplant Research
Healthy
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Peripheral blood stem cells (PBSCs) collected following stimulation with filgrastim are commonly used for autologous hematopoietic transplants.
- Trial name
- NCT00511550
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Healthy
G-CSF for Granulocyte Donation
This study will examine the feasibility of giving cell growth stimulants to granulocyte donors the same day of donation rather than the day before.
- Trial name
- NCT00001842
- Testing
- Granulocyte colony-stimulating factor, Dexamethasone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Tuberculosis, Immunologic Activity Alteration
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
The goal of this observational study is to learn about how the blood leucocytes from patients with and without exposure or disease from tuberculosis (TB) are able to kill live mycobacteria (M. tuberculosis).
- Trial name
- MGIA (NCT06580639)
- Testing
- No intervention.
- Where
- 2 sites in Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Linkoeping University
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Hematopoietic Stem Cell Mobilization
Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors
Data collection on the safety and efficacy of Zarzio® / Filgrastim HEXAL® in adult healthy unrelated stem cell donors undergoing peripheral blood progenitor cell mobilization.
- Trial name
- SMART (NCT01766934)
- Where
- 2 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Sandoz
Blood Donors, Apheresis
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Background: Many different research projects need a steady supply of human blood. Blood donated by screened, healthy people may be used to test new drugs, for example, or to learn how blood cells work.
- Trial name
- NCT07877259
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers
Phase I study to determine and compare the safety/tolerability of single ascending doses of POL6326 by intravenous infusion.
- Trial name
- NCT01841476
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Healthy Donors, HIV Positive
Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
To test blood samples from volunteer donors of whole blood and blood components using a new investigational test that detects human immunodeficiency virus (HIV) infection.
- Trial name
- NCT00686205
- Testing
- collection of follow-up sample based on PRISM HIV O Plus result
- Where
- 7 sites in United States
- Volunteers
- 24,111 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Meningitis, Meningococcal
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
The purpose of this study was to collect large volumes of matched pairs of pre- and post-vaccination sera from healthy subjects who administered GlaxoSmithKline (GSK) Biologicals' vaccine against meningitis- MenACWY vaccine…
- Trial name
- NCT03493919
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- Where
- 6 sites in Australia, Germany
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Cytapheresis of Volunteer Donors
Background: National Institute on Aging researchers are looking at studies that require large numbers of white blood cells for lab use. Standard blood samples do not provide enough white blood cells for these studies.
- Trial name
- NCT00104325
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
HPV 16 Infection, HPV-Related Carcinoma
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
This healthy related donor clinical trial is linked to a recipient clinical trial protocol for therapeutic purposes. In this healthy donor protocol, haploidentical relatives of a patient with recurrent or metastatic human…
- Conditions
- HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
- Trial name
- J21112LINKED (NCT06508138)
- Testing
- pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins